Search

Your search keyword '"Deik A"' showing total 40 results
Start Over Author "Deik A" Publisher wiley
40 results on '"Deik A"'

1. Tau maturation in the clinicopathological spectrum of Lewy body and Alzheimer's disease

Author

Sanaz Arezoumandan, Katheryn A.Q. Cousins, Daniel T. Ohm, MaKayla Lowe, Min Chen, James Gee, Jeffrey S. Phillips, Corey T. McMillan, Kelvin C. Luk, Andres Deik, Meredith A. Spindler, Thomas F. Tropea, Daniel Weintraub, David A. Wolk, Murray Grossman, Virginia Lee, Alice S. Chen‐Plotkin, Edward B. Lee, and David J. Irwin

Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429
Abstract

Abstract Objective Alzheimer's disease neuropathologic change and alpha‐synucleinopathy commonly co‐exist and contribute to the clinical heterogeneity of dementia. Here, we examined tau epitopes marking various stages of tangle maturation to test the hypotheses that tau maturation is more strongly associated with beta‐amyloid compared to alpha‐synuclein, and within the context of mixed pathology, mature tau is linked to Alzheimer's disease clinical phenotype and negatively associated with Lewy body dementia. Methods We used digital histology to measure percent area‐occupied by pathology in cortical regions among individuals with pure Alzheimer's disease neuropathologic change, pure alpha‐synucleinopathy, and a co‐pathology group with both Alzheimer's and alpha‐synuclein pathologic diagnoses. Multiple tau monoclonal antibodies were used to detect early (AT8, MC1) and mature (TauC3) epitopes of tangle progression. We used linear/logistic regression to compare groups and test the association between pathologies and clinical features. Results There were lower levels of tau pathology (β = 1.86–2.96, p

Published
2024
Full Text
View/download PDF

2. Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease

Author

Katheryn A. Q. Cousins, David J. Irwin, Alice Chen‐Plotkin, Leslie M. Shaw, Sanaz Arezoumandan, Edward B. Lee, David A. Wolk, Daniel Weintraub, Meredith Spindler, Andres Deik, Murray Grossman, and Thomas F. Tropea

Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429
Abstract

Abstract Objective Within Lewy body spectrum disorders (LBSD) with α‐synuclein pathology (αSyn), concomitant Alzheimer's disease (AD) pathology is common and is predictive of clinical outcomes, including cognitive impairment and decline. Plasma phosphorylated tau 181 (p‐tau181) is sensitive to AD neuropathologic change (ADNC) in clinical AD, and plasma glial fibrillary acidic protein (GFAP) is associated with the presence of β‐amyloid plaques. While these plasma biomarkers are well tested in clinical and pathological AD, their diagnostic and prognostic performance for concomitant AD in LBSD is unknown. Methods In autopsy‐confirmed αSyn‐positive LBSD, we tested how plasma p‐tau181 and GFAP differed across αSyn with concomitant ADNC (αSyn+AD; n = 19) and αSyn without AD (αSyn; n = 30). Severity of burden was scored on a semiquantitative scale for several pathologies (e.g., β‐amyloid and tau), and scores were averaged across sampled brainstem, limbic, and neocortical regions. Results Linear models showed that plasma GFAP was significantly higher in αSyn+AD compared to αSyn (β = 0.31, 95% CI = 0.065–0.56, and P = 0.015), after covarying for age at plasma, plasma‐to‐death interval, and sex; plasma p‐tau181 was not (P = 0.37). Next, linear models tested associations of AD pathological features with both plasma analytes, covarying for plasma‐to‐death, age at plasma, and sex. GFAP was significantly associated with brain β‐amyloid (β = 15, 95% CI = 6.1–25, and P = 0.0018) and tau burden (β = 12, 95% CI = 2.5–22, and P = 0.015); plasma p‐tau181 was not associated with either (both P > 0.34). Interpretation Findings indicate that plasma GFAP may be sensitive to concomitant AD pathology in LBSD, especially accumulation of β‐amyloid plaques.

Published
2023
Full Text
View/download PDF

3. Tau maturation in the clinicopathological spectrum of Lewy body and Alzheimer's disease

Author

Arezoumandan, Sanaz, primary, Cousins, Katheryn A.Q., additional, Ohm, Daniel T., additional, Lowe, MaKayla, additional, Chen, Min, additional, Gee, James, additional, Phillips, Jeffrey S., additional, McMillan, Corey T., additional, Luk, Kelvin C., additional, Deik, Andres, additional, Spindler, Meredith A., additional, Tropea, Thomas F., additional, Weintraub, Daniel, additional, Wolk, David A., additional, Grossman, Murray, additional, Lee, Virginia, additional, Chen‐Plotkin, Alice S., additional, Lee, Edward B., additional, and Irwin, David J., additional

Published
2024
Full Text
View/download PDF

5. Plasma glial fibrillary acidic protein is associated with concomitant brain β‐amyloid in Lewy body disease

Author

Cousins, Katheryn A Q, primary, Irwin, David J., additional, Chen‐Plotkin, Alice, additional, Shaw, Leslie M., additional, Arezoumandan, Sanaz, additional, Lee, Eddie B, additional, Wolk, David A., additional, Weintraub, Daniel, additional, Spindler, Meredith, additional, Deik, Andres, additional, Grossman, Murray, additional, and Tropea, Thomas F., additional

Published
2023
Full Text
View/download PDF

6. APOE4 impairs microglia‐astrocyte response in Alzheimer’s disease by inducing TGFβ‐mediated checkpoints

Author

Butovsky, Oleg, primary, Yin, Zhuoran, additional, Rosenzweig, Neta, additional, Kleemann, Kilian, additional, Zhang, Xiaoming, additional, Brandao, Wesley N, additional, Margeta, Milica, additional, Schroeder, Caitlin M, additional, Silveira, Sebastian, additional, Gauthier, Christian, additional, Mallah, Dania, additional, Pitts, Kristen, additional, Durao, Ana, additional, Herron, Shawn, additional, Shorey, Hannah, additional, Cheng, Yiran, additional, Barry, Jen‐Li, additional, Wakelin, Sam, additional, Rhee, Jared, additional, Yung, Anthony, additional, Aronchik, Michael, additional, Wang, Chao, additional, Jain, Nimansha, additional, Bao, Xin, additional, Gerrits, Emma, additional, Brouwer, Nieske, additional, Deik, Amy, additional, Tenen, Daniel G., additional, Ikezu, Tsuneya, additional, Santander, Nicolas G., additional, McKinsey, Gabriel L., additional, Baufeld, Caroline, additional, Sheppard, Dean, additional, Krasemann, Susanne, additional, Eggen, Bart, additional, Clish, Clary, additional, Tanzi, Rudolph E., additional, Madore, Charlotte, additional, Arnold, Thomas D., additional, and Holtzman, David M., additional

Published
2023
Full Text
View/download PDF

7. APOE4 impairs Microglia ‐ Astrocyte Crosstalk in Alzheimer Disease

Author

Kleemann, Kilian, primary, Rosenzweig, Neta, additional, Yin, Zhuoran, additional, Zhang, Xiaoming, additional, Brandao, Wesley N, additional, Margeta, Milica, additional, Schroeder, Caitlin M, additional, Silveira, Sebastian, additional, Gauthier, Christian, additional, Mallah, Dania, additional, Pitts, Kristen, additional, Herron, Shawn, additional, Shorey, Hannah, additional, Aronchik, Michael, additional, Wang, Chao, additional, Jain, Nimansha, additional, Bao, Xin, additional, Brouwer, Nieske, additional, Baufeld, Caroline, additional, Krasemann, Susanne, additional, Eggen, Bart, additional, Clish, Clary, additional, Tanzi, Rudolph E., additional, Madore, Charlotte, additional, Wakelin, Sam, additional, Rhee, Jared, additional, Cheng, Yiran, additional, Barry, Jen‐Li, additional, Yung, Anthony, additional, Gerrits, Emma, additional, Deik, Amy, additional, Tenen, Daniel G., additional, Santander, Nicolas G., additional, Ikezu, Tsuneya, additional, McKinsey, Gabriel L., additional, Sheppard, Dean, additional, Arnold, Thomas D., additional, Durao, Ana, additional, Holtzman, David M., additional, and Butovsky, Oleg, additional

Published
2023
Full Text
View/download PDF

8. Tau maturation in clinicopathological spectrum of Lewy body and Alzheimer’s disease

Author

Arezoumandan, Sanaz, primary, Cousins, Katheryn A Q, additional, Ohm, Daniel T, additional, Lowe, MaKayla, additional, Phillips, Jeffrey S, additional, McMillan, Corey T, additional, Siderowf, Andrew, additional, Chen‐Plotkin, Alice, additional, Deik, Andres, additional, Spindler, Meredith, additional, Tropea, Thomas F., additional, Weintraub, Daniel, additional, Wolk, David A., additional, Grossman, Murray, additional, Lee, Eddie B, additional, and Irwin, David J., additional

Published
2023
Full Text
View/download PDF

9. Hardened faecal pellets as a significant component in deep water, subtropical marine environments

Author

Hanaa Deik, Lars Reuning, Benjamin Petrick, and Hideko Takayanagi

Subjects
Australian Shelf, early cementation, IODP, non‐skeletal grain, peloid, subtropical carbonate, Geology, QE1-996.5
Abstract

Abstract Non‐skeletal carbonate grains are classically interpreted to form in shallow, tropical environments. Peloids deposited in deep, subtropical marine conditions are poorly studied. IODP site U1460 on the subtropical Carnarvon Ramp (Southwest Shelf of Australia) recovered a nearly continuous Pliocene to Recent record of outer shelf and slope sediments. The relative abundance of peloids varies between 0% and 67% of the fine to medium sand fraction, and contributes on average ~4% of all grains. The origin and composition of these peloids were investigated using scanning electron microscopy equipped with an energy‐dispersive X‐ray spectrometer, light microscopy, X‐ray diffraction and stable isotope analysis. The peloids have a uniform size and shape and are interpreted as faecal pellets. They are mainly composed of skeletal fragments such as ascidian spicules, planktic foraminifera and sponge spicules in a mud‐sized matrix containing abundant coccolith plates. Mineralogical analysis show that the pellets consist of aragonite, calcite and dolomite. The pellets have an identical mineralogical composition and skeletal assemblage as the surrounding matrix, indicating that they have formed in situ. They occur more abundantly during interglacials when the site was situated in deeper waters below the swell wave base, presumably because the pellets were protected from disintegration and therefore available for cementation. The presence of framboidal pyrite within the pellets indicates bacterial sulphate reduction (BSR). The reduction of iron by hydrogen sulphide produced during BSR decreases the pH and likely explains the observed aragonite dissolution. Aragonite dissolution likely increases the alkalinity, and in consequence causes the precipitation of calcite and dolomite cements. It is suggested here that pellets are hardened due to this early cementation close to the sea floor increasing the potential for preservation in the fossil record.

Published
2019
Full Text
View/download PDF

10. Metabolomic Profiling of Left Ventricular Diastolic Dysfunction in Women With or at Risk for HIV Infection: The Women's Interagency HIV Study

Author

Claudio A. Bravo, Simin Hua, Amy Deik, Jason Lazar, David B. Hanna, Justin Scott, Jin Choul Chai, Robert C. Kaplan, Kathryn Anastos, Octavio A. Robles, Clary B. Clish, Jorge R. Kizer, and Qibin Qi

Subjects
heart failure, HIV, left ventricular diastolic dysfunction, metabolomics, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Background People living with HIV have an increased risk of left ventricular diastolic dysfunction (LVDD) and heart failure. HIV‐associated LVDD may reflect both cardiomyocyte and systemic metabolic derangements, but the underlying pathways remain unclear. Methods and Results To explore such pathways, we conducted a pilot study in the Bronx and Brooklyn sites of the WIHS (Women's Interagency HIV Study) who participated in concurrent, but separate, metabolomics and echocardiographic ancillary studies. Liquid chromatography tandem mass spectrometry–based metabolomic profiling was performed on plasma samples from 125 HIV‐infected (43 with LVDD) and 35 HIV‐uninfected women (9 with LVDD). Partial least squares discriminant analysis identified polar metabolites and lipids in the glycerophospholipid‐metabolism and fatty‐acid‐oxidation pathways associated with LVDD. After multivariable adjustment, LVDD was significantly associated with higher concentrations of diacylglycerol 30:0 (odds ratio [OR], 1.60, 95% CI [1.01–2.55]); triacylglycerols 46:0 (OR 1.60 [1.04–2.48]), 48:0 (OR 1.63 [1.04–2.54]), 48:1 (OR 1.62 [1.01–2.60]), and 50:0 (OR 1.61 [1.02–2.53]); acylcarnitine C7 (OR 1.88 [1.21–2.92]), C9 (OR 1.99 [1.27–3.13]), and C16 (OR 1.80 [1.13–2.87]); as well as lower concentrations of phosphocholine (OR 0.59 [0.38–0.91]). There was no evidence of effect modification of these relationships by HIV status. Conclusions In this pilot study, women with or at risk of HIV with LVDD showed alterations in plasma metabolites in the glycerophospholipid‐metabolism and fatty‐acid‐oxidation pathways. Although these findings require replication, they suggest that improved understanding of metabolic perturbations and their potential modification could offer new approaches to prevent cardiac dysfunction in this high‐risk group.

Published
2020
Full Text
View/download PDF

11. Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease

Author

Cousins, Katheryn A. Q., primary, Irwin, David J., additional, Chen‐Plotkin, Alice, additional, Shaw, Leslie M., additional, Arezoumandan, Sanaz, additional, Lee, Edward B., additional, Wolk, David A., additional, Weintraub, Daniel, additional, Spindler, Meredith, additional, Deik, Andres, additional, Grossman, Murray, additional, and Tropea, Thomas F., additional

Published
2023
Full Text
View/download PDF

13. Plasma Metabolite Profiles Associated with the Amount and Source of Meat and Fish Consumption and the Risk of Type 2 Diabetes

Author

García‐Gavilán, Jesús, primary, Nishi, Stephanie K., additional, Paz‐Graniel, Indira, additional, Guasch‐Ferré, Marta, additional, Razquin, Cristina, additional, Clish, Clary B., additional, Toledo, Estefanía, additional, Ruiz‐Canela, Miguel, additional, Corella, Dolores, additional, Deik, Amy, additional, Drouin‐Chartier, Jean‐Philippe, additional, Wittenbecher, Clemens, additional, Babio, Nancy, additional, Estruch, Ramon, additional, Ros, Emilio, additional, Fitó, Montserrat, additional, Arós, Fernando, additional, Fiol, Miquel, additional, Serra‐Majem, Lluís, additional, Liang, Liming, additional, Martínez‐González, Miguel A., additional, Hu, Frank B., additional, and Salas‐Salvadó, Jordi, additional

Published
2022
Full Text
View/download PDF

15. Tau pathology associates with in vivo cortical thinning in Lewy body disorders

Author

James F. Morley, Nabila Dahodwala, Leslie M. Shaw, John E. Duda, John Q. Trojanowski, Murray Grossman, Sanjeev N. Vaishnavi, David G. Coughlin, Corey T. McMillan, Alice Chen-Plotkin, David A. Wolk, Meredith Spindler, David J. Irwin, Christopher Olm, Nicola Spotorno, Daniel Weintraub, Andres Deik, and Edward B. Lee

Subjects
Male, 0301 basic medicine, Aging, Pathology, Neocortex, Autopsy, Comorbidity, Neurodegenerative, Alzheimer's Disease, 0302 clinical medicine, 2.1 Biological and endogenous factors, Aetiology, Alzheimer's Disease Related Dementias (ADRD), Research Articles, Parkinson's Disease, General Neuroscience, Neurodegeneration, Parkinson Disease, Middle Aged, medicine.anatomical_structure, Neurological, Female, hormones, hormone substitutes, and hormone antagonists, Research Article, Lewy Body Disease, medicine.medical_specialty, Lewy Body Dementia, Clinical Sciences, tau Proteins, 03 medical and health sciences, Atrophy, Alzheimer Disease, In vivo, Acquired Cognitive Impairment, medicine, Humans, Dementia, Cognitive Dysfunction, Retrospective Studies, Aged, Lewy body, business.industry, Prevention, Neurosciences, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), medicine.disease, Brain Disorders, 030104 developmental biology, Histopathology, Neurology (clinical), business, 030217 neurology & neurosurgery
Abstract

ObjectivesTo investigate the impact of Alzheimer's disease (AD) co-pathology on an in vivo structural measure of neurodegeneration in Lewy body disorders (LBD).MethodsWe studied 72 LBD patients (Parkinson disease (PD)=2, PD-MCI=25, PD with dementia=10, dementia with Lewy bodies=35) with either CSF analysis or neuropathological examination and structural MRI during life. The cohort was divided into those harboring significant AD co-pathology, either at autopsy (intermediate/high AD neuropathologic change) or with CSF signature indicating AD co-pathology (t-tau/Aβ1-42 >0.3) (LBD+AD, N=19), and those without AD co-pathology (LBD-AD, N=53). We also included a reference group of 25 patients with CSF biomarker-confirmed amnestic AD. We investigated differences in MRI cortical thickness estimates between groups, and in the 21 autopsied LBD patients (LBD-AD=14, LBD+AD=7), directly tested the association between antemortem MRI and post-mortem burdens of tau, Aβ, and alpha-synuclein using digital histopathology in five representative neocortical regions.ResultsThe LBD+AD group was characterized by cortical thinning in anterior/medial and lateral temporal regions (P&nbsp

Published
2020

16. Predictive modeling of spread in adult‐onset isolated dystonia: Key properties and effect of tremor inclusion

Author

Wang, Meng, primary, Sajobi, Tolulope, additional, Morgante, Francesca, additional, Adler, Charles, additional, Agarwal, Pinky, additional, Bäumer, Tobias, additional, Berardelli, Alfredo, additional, Berman, Brian D., additional, Blumin, Joel, additional, Borsche, Max, additional, Brashear, Allison, additional, Deik, Andres, additional, Duque, Kevin, additional, Espay, Alberto J., additional, Ferrazzano, Gina, additional, Feuerstein, Jeanne, additional, Fox, Susan, additional, Frank, Samuel, additional, Hallett, Mark, additional, Jankovic, Joseph, additional, LeDoux, Mark S., additional, Leegwater‐Kim, Julie, additional, Mahajan, Abhimanyu, additional, Malaty, Irene A., additional, Ondo, William, additional, Pantelyat, Alexander, additional, Pirio‐Richardson, Sarah, additional, Roze, Emmanuel, additional, Saunders‐Pullman, Rachel, additional, Suchowersky, Oksana, additional, Truong, Daniel, additional, Vidailhet, Marie, additional, Shukla, Aparna Wagle, additional, Perlmutter, Joel S., additional, Jinnah, Hyder A., additional, and Martino, Davide, additional

Published
2021
Full Text
View/download PDF

17. PPP2R5DGenetic Mutations and Early‐Onset Parkinsonism

Author

Walker, Ian M., primary, Riboldi, Giulietta M., additional, Drummond, Patrick, additional, Saade‐Lemus, Sandra, additional, Martin‐Saavedra, Juan Sebastian, additional, Frucht, Steven, additional, Bardakjian, Tanya M., additional, Gonzalez‐Alegre, Pedro, additional, and Deik, Andres, additional

Published
2020
Full Text
View/download PDF

18. Tau pathology associates with in vivo cortical thinning in Lewy body disorders

Author

Spotorno, Nicola, primary, Coughlin, David G., additional, Olm, Christopher A., additional, Wolk, David, additional, Vaishnavi, Sanjeev N., additional, Shaw, Leslie M., additional, Dahodwala, Nabila, additional, Morley, James F., additional, Duda, John E., additional, Deik, Andres F., additional, Spindler, Meredith A., additional, Chen‐Plotkin, Alice, additional, Lee, Edward B., additional, Trojanowski, John Q., additional, McMillan, Corey T., additional, Weintraub, Daniel, additional, Grossman, Murray, additional, and Irwin, David J., additional

Published
2020
Full Text
View/download PDF

20. Plasma Metabolomics Profiles are Associated with the Amount and Source of Protein Intake: A Metabolomics Approach within the PREDIMED Study

Author

Hernández‐Alonso, Pablo, primary, Becerra‐Tomás, Nerea, additional, Papandreou, Christopher, additional, Bulló, Mònica, additional, Guasch‐Ferré, Marta, additional, Toledo, Estefanía, additional, Ruiz‐Canela, Miguel, additional, Clish, Clary B., additional, Corella, Dolores, additional, Dennis, Courtney, additional, Deik, Amy, additional, Wang, Dong D., additional, Razquin, Cristina, additional, Drouin‐Chartier, Jean‐Philippe, additional, Estruch, Ramon, additional, Ros, Emilio, additional, Fitó, Montserrat, additional, Arós, Fernando, additional, Fiol, Miquel, additional, Serra‐Majem, Lluís, additional, Liang, Liming, additional, Martínez‐González, Miguel A, additional, Hu, Frank B, additional, and Salas‐Salvadó, Jordi, additional

Published
2020
Full Text
View/download PDF

21. <scp> PPP2R5D </scp> Genetic Mutations and Early‐Onset Parkinsonism

Author

Andres Deik, Pedro Gonzalez-Alegre, Juan Sebastian Martin-Saavedra, Patrick Drummond, Steven J. Frucht, Sandra Saade-Lemus, Ian M Walker, Tanya Bardakjian, and Giulietta Riboldi

Subjects
Pediatrics, medicine.medical_specialty, Neurology, business.industry, MEDLINE, Medicine, Neurology (clinical), Early onset parkinsonism, business
Published
2020

23. Plasma Metabolites Associated with Frequent Red Wine Consumption: A Metabolomics Approach within the PREDIMED Study

Author

Hernández‐Alonso, Pablo, primary, Papandreou, Christopher, additional, Bulló, Mònica, additional, Ruiz‐Canela, Miguel, additional, Dennis, Courtney, additional, Deik, Amy, additional, Wang, Dong D., additional, Guasch‐Ferré, Marta, additional, Yu, Edward, additional, Toledo, Estefanía, additional, Razquin, Cristina, additional, Corella, Dolores, additional, Estruch, Ramon, additional, Ros, Emilio, additional, Fitó, Montserrat, additional, Arós, Fernando, additional, Fiol, Miquel, additional, Serra‐Majem, Lluís, additional, Liang, Liming, additional, Clish, Clary B., additional, Martínez‐González, Miguel A, additional, Hu, Frank B, additional, and Salas‐Salvadó, Jordi, additional

Published
2019
Full Text
View/download PDF

25. Atypical presentation of late-onset Tay-sachs disease

Author

Rachel Saunders-Pullman and Andres Deik

Subjects
congenital, hereditary, and neonatal diseases and abnormalities, medicine.medical_specialty, Pathology, Ataxia, Physiology, Tay-Sachs disease, nutritional and metabolic diseases, Late onset, Disease, Progressive muscular atrophy, medicine.disease, Cellular and Molecular Neuroscience, Endocrinology, Physiology (medical), Internal medicine, medicine, Lysosomal storage disease, Hexosaminidase, Neurology (clinical), medicine.symptom, Presentation (obstetrics), Psychology
Abstract

Introduction Late-onset Tay-Sachs disease (LOTS) is a lysosomal storage disease caused by deficient Beta-hexosaminidase A activity.

Published
2014

26. Heterogeneity in primary dystonia: Lessons from THAP1 , GNAL , and TOR1A in Amish-Mennonites

Author

Andres Deik, Roberto A. Ortega, Tania Fuchs, Alison Brashear, Rachel Saunders-Pullman, Laurie J. Ozelius, Marta San Luciano, Deborah Raymond, and Susan B. Bressman

Subjects
Dystonia, Genetics, congenital, hereditary, and neonatal diseases and abnormalities, education.field_of_study, Genetic heterogeneity, Population, Ethnic group, Primary Dystonia, Biology, medicine.disease, nervous system diseases, Neurology, Mutation (genetic algorithm), otorhinolaryngologic diseases, medicine, Neurology (clinical), education, Founder mutation, Dystonic disorder
Abstract

Background A founder mutation in the THAP1 gene causing primary dystonia was originally described in the Amish-Mennonites. However there may be both genotypic and phenotypic heterogeneity of dystonia in this population that may also inform studies in other ethnic groups.

Published
2014

27. Increased substantia nigra echogenicity in LRRK2 family members without mutations

Author

Rachel Saunders-Pullman, Susan Bressman, Mariel Y. Pullman, Nir Giladi, Roberto Angel Ortega, Andres Deik, Johann Hagenah, Norbert Brüggemann, Karen Marder, Deborah Raymond, and Amanda Glickman

Subjects
0301 basic medicine, Family health, Pathology, medicine.medical_specialty, business.industry, Extramural, Echogenicity, Substantia nigra, 030105 genetics & heredity, LRRK2, 03 medical and health sciences, 0302 clinical medicine, Text mining, Neurology, medicine, Neurology (clinical), Ultrasonography, business, 030217 neurology & neurosurgery
Published
2018

28. Plasma Metabolites Associated with Frequent Red Wine Consumption: A Metabolomics Approach within the PREDIMED Study

Author

Dong D. Wang, Fernando Arós, Edward Yu, Marta Guasch-Ferré, Clary B. Clish, Miquel Fiol, Montserrat Fitó, Mònica Bulló, Cristina Razquin, Liming Liang, Emilio Ros, Miguel Ángel Martínez-González, Miguel Ruiz-Canela, Christopher Papandreou, Jordi Salas-Salvadó, Courtney Dennis, Amy Deik, Frank B. Hu, Pablo Hernández-Alonso, Dolores Corella, Lluis Serra-Majem, Ramon Estruch, and Estefanía Toledo

Subjects
Male, 0301 basic medicine, Population, Wine, Biology, Sensitivity and Specificity, Article, Eating, 03 medical and health sciences, Metabolomics, Linear regression, Humans, Food science, education, Aged, education.field_of_study, 030109 nutrition & dietetics, Receiver operating characteristic, Smoking, Area under the curve, Regression analysis, Middle Aged, Predimed, Diet, Blood, Cross-Sectional Studies, 030104 developmental biology, Area Under Curve, Female, Food Science, Biotechnology
Abstract

SCOPE: The relationship between red wine (RW) consumption and metabolism is poorly understood. We aimed to assess the systemic metabolomic profiles in relation to frequent RW consumption as well as the ability of a set of metabolites to discriminate RW consumers. METHODS AND RESULTS: Cross-sectional analysis of 1,157 participants. Subjects were divided as non-RW consumers versus RW consumers (> 1 glass/day RW (100 mL/day)). Plasma metabolomics analysis was performed using LC-MS. Associations between 386 identified metabolites and RW consumption were assessed using elastic net regression analysis taking into consideration baseline significant covariates. Ten-cross-validation (CV) was performed and receiver operating characteristic curves were constructed in each of the validation datasets based on weighted models. A subset of 13 metabolites was consistently selected and discriminated RW consumers versus non-consumers. Based on the multi-metabolite model weighted with the regression coefficients of metabolites, the area under the curve was 0.83 (95% CI: 0.80–0.86). These metabolites mainly consisted of lipid species (e.g. triglycerides and phosphatidylcholines), some organic acids and alkaloids. CONCLUSIONS: A multi-metabolite model identified in a Mediterranean population appeared useful to discriminate between frequent RW consumers and non-consumers. Further studies are needed to assess the contribution of these metabolites in health and disease.

Published
2019

31. Parkinson disease phenotype in Ashkenazi jews with and withoutLRRK2G2019S mutations

Author

Mark Groves, Vicki Shanker, Diana Ruiz, Marta San Luciano, Mali Gana Weisz, Tanya Gurevich, Nir Giladi, Karen Marder, Elan D. Louis, Anat Mirelman, Ming X. Tang, Laurie J. Ozelius, Rivka Sachdev, Naomi Lubarr, Tsvyatko Dorovski, Harini Sarva, Joan Miravite, Ernest Roos, Roberto A. Ortega, Llency Rosado, Helen Mejia Santana, Deborah Raymond, Cheryl Waters, Christina Palmese, Lucien J. Cote, Kira Yasinovsky, Andres Deik, Susan Bressman, Maayan Zalis, Lawrence Severt, Blair Ford, Oren A. Levy, Lorraine N. Clark, Matthew Swan, Jeannie Soto-Valencia, Michael W. Pauciulo, Avi Orr-Urtreger, William C. Nichols, Stanley Fahn, Pietro Mazzoni, Martha Orbe-Reilly, Ann L. Hunt, Roy N. Alcalay, Avner Thaler, Jose Cabassa, Brooke Johannes, Matthew J. Barrett, Anat Bar Shira, and Rachel Saunders-Pullman

Subjects
medicine.medical_specialty, business.industry, Montreal Cognitive Assessment, Disease, LRRK2, Ashkenazi jews, nervous system diseases, Neurology, Internal medicine, Genotype, Severity of illness, Physical therapy, Medicine, Geriatric Depression Scale, Neurology (clinical), business, Glucocerebrosidase
Abstract

The phenotype of Parkinson's disease (PD) in patients with and without leucine-rich repeat kinase 2 (LRRK2) G2019S mutations reportedly is similar; however, large, uniformly evaluated series are lacking. The objective of this study was to characterize the clinical phenotype of Ashkenazi Jewish (AJ) PD carriers of the LRRK2 G2019S mutation. We studied 553 AJ PD patients, including 65 patients who were previously reported, from three sites (two in New York and one in Tel-Aviv). Glucocerebrosidase (GBA) mutation carriers were excluded. Evaluations included the Montreal Cognitive Assessment (MoCA), the Unified Parkinson's Disease Rating Scale (UPDRS), the Geriatric Depression Scale (GDS) and the Non-Motor Symptoms (NMS) questionnaire. Regression models were constructed to test the association between clinical and demographic features and LRRK2 status (outcome) in 488 newly recruited participants. LRRK2 G2019S carriers (n = 97) and non-carriers (n = 391) were similar in age and age at onset of PD. Carriers had longer disease duration (8.6 years vs. 6.1 years; P 5 years (P = 0.042). Performance on the UPDRS, MoCA, GDS, and NMS did not differ by mutation status. PD in AJ LRRK2 G2019S mutation carriers is similar to idiopathic PD but is characterized by more frequent lower extremity involvement at onset and PIGD without the associated cognitive impairment.

Published
2013

32. Circulating branched-chain amino acid concentrations are associated with obesity and future insulin resistance in children and adolescents

Author

Thomas J. Wang, Clary B. Clish, Meaghan A. McCarthy, Steven K. Grinspoon, Amy Fleischman, Shana E. McCormack, Amy Deik, Oded Shaham, Vamsi K. Mootha, and Robert E. Gerszten

Subjects
medicine.medical_specialty, Nutrition and Dietetics, business.industry, Health Policy, Branched-chain amino acid, Public Health, Environmental and Occupational Health, Type 2 diabetes, Overweight, medicine.disease, Obesity, chemistry.chemical_compound, Insulin resistance, Endocrinology, Overnutrition, chemistry, Internal medicine, Diabetes mellitus, Pediatrics, Perinatology and Child Health, medicine, medicine.symptom, business, Body mass index
Abstract

SummaryWhat is already known about this subject Circulating concentrations of branched-chain amino acids (BCAAs) can affect carbohydrate metabolism in skeletal muscle, and therefore may alter insulin sensitivity. BCAAs are elevated in adults with diet-induced obesity, and are associated with their future risk of type 2 diabetes even after accounting for baseline clinical risk factors. What this study adds Increased concentrations of BCAAs are already present in young obese children and their metabolomic profiles are consistent with increased BCAA catabolism. Elevations in BCAAs in children are positively associated with insulin resistance measured 18 months later, independent of their initial body mass index. Background Branched-chain amino acid (BCAA) concentrations are elevated in response to overnutrition, and can affect both insulin sensitivity and secretion. Alterations in their metabolism may therefore play a role in the early pathogenesis of type 2 diabetes in overweight children. Objective To determine whether paediatric obesity is associated with elevations in fasting circulating concentrations of BCAAs (isoleucine, leucine and valine), and whether these elevations predict future insulin resistance. Methods Sixty-nine healthy subjects, ages 8–18 years, were enrolled as a cross-sectional cohort. A subset of subjects who were pre- or early-pubertal, ages 8–13 years, were enrolled in a prospective longitudinal cohort for 18 months (n = 17 with complete data). Results Elevations in the concentrations of BCAAs were significantly associated with body mass index (BMI) Z-score (Spearman's Rho 0.27, P = 0.03) in the cross-sectional cohort. In the subset of subjects that followed longitudinally, baseline BCAA concentrations were positively associated with homeostasis model assessment for insulin resistance measured 18 months later after controlling for baseline clinical factors including BMI Z-score, sex and pubertal stage (P = 0.046). Conclusions Elevations in the concentrations of circulating BCAAs are significantly associated with obesity in children and adolescents, and may independently predict future insulin resistance.

Published
2012

37. Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations

Author

Alcalay, Roy N., primary, Mirelman, Anat, additional, Saunders‐Pullman, Rachel, additional, Tang, Ming‐X, additional, Mejia Santana, Helen, additional, Raymond, Deborah, additional, Roos, Ernest, additional, Orbe‐Reilly, Martha, additional, Gurevich, Tanya, additional, Bar Shira, Anat, additional, Gana Weisz, Mali, additional, Yasinovsky, Kira, additional, Zalis, Maayan, additional, Thaler, Avner, additional, Deik, Andres, additional, Barrett, Matthew James, additional, Cabassa, Jose, additional, Groves, Mark, additional, Hunt, Ann L., additional, Lubarr, Naomi, additional, San Luciano, Marta, additional, Miravite, Joan, additional, Palmese, Christina, additional, Sachdev, Rivka, additional, Sarva, Harini, additional, Severt, Lawrence, additional, Shanker, Vicki, additional, Swan, Matthew Carrington, additional, Soto‐Valencia, Jeannie, additional, Johannes, Brooke, additional, Ortega, Robert, additional, Fahn, Stanley, additional, Cote, Lucien, additional, Waters, Cheryl, additional, Mazzoni, Pietro, additional, Ford, Blair, additional, Louis, Elan, additional, Levy, Oren, additional, Rosado, Llency, additional, Ruiz, Diana, additional, Dorovski, Tsvyatko, additional, Pauciulo, Michael, additional, Nichols, William, additional, Orr‐Urtreger, Avi, additional, Ozelius, Laurie, additional, Clark, Lorraine, additional, Giladi, Nir, additional, Bressman, Susan, additional, and Marder, Karen S., additional

Published
2013
Full Text
View/download PDF

40. Physical performance and plasma metabolic profile as potential prognostic factors in metastatic lung cancer patients.

Author

das Neves W, Alves CRR, Dos Santos G, Alves MNN, Deik A, Pierce K, Dennis C, Buckley L, Clish CB, Swoboda KJ, Brum PC, and de Castro Junior G

Subjects
Humans, Male, Female, Middle Aged, Prognosis, Aged, Prospective Studies, Metabolome physiology, Case-Control Studies, Oxygen Consumption physiology, Survival Rate, Quality of Life, Muscle Fibers, Skeletal metabolism, Cell Proliferation, Walk Test, Lung Neoplasms metabolism, Lung Neoplasms blood, Lung Neoplasms pathology, Carcinoma, Non-Small-Cell Lung metabolism, Carcinoma, Non-Small-Cell Lung blood, Carcinoma, Non-Small-Cell Lung pathology, Body Composition, Physical Functional Performance
Abstract

Background: Low physical performance is associated with higher mortality rate in multiple pathological conditions. Here, we aimed to determine whether body composition and physical performance could be prognostic factors in non-small cell lung cancer (NSCLC) patients. Moreover, we performed an exploratory approach to determine whether plasma samples from NSCLC patients could directly affect metabolic and structural phenotypes in primary muscle cells., Methods: This prospective cohort study included 55 metastatic NSCLC patients and seven age-matched control subjects. Assessments included physical performance, body composition, quality of life and overall survival rate. Plasma samples from a sub cohort of 18 patients were collected for exploratory studies in cell culture and metabolomic analysis., Results: We observed a higher survival rate in NSCLC patients with high performance in the timed up-and-go (+320%; p = .007), sit-to-stand (+256%; p = .01) and six-minute walking (+323%; p = .002) tests when compared to NSCLC patients with low physical performance. There was no significant association for similar analysis with body composition measurements (p > .05). Primary human myotubes incubated with plasma from NSCLC patients with low physical performance had impaired oxygen consumption rate (-54.2%; p < .0001) and cell proliferation (-44.9%; p = .007). An unbiased metabolomic analysis revealed a list of specific metabolites differentially expressed in the plasma of NSCLC patients with low physical performance., Conclusion: These novel findings indicate that physical performance is a prognostic factor for overall survival in NSCLC patients and provide novel insights into circulating factors that could impair skeletal muscle metabolism., (© 2024 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results